Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
27.08
+1.53 (5.99%)
Dec 6, 2024, 4:00 PM EST - Market closed
Spyre Therapeutics Revenue
In the year 2023, Spyre Therapeutics had annual revenue of $886.00K, down -61.96%.
Revenue (ttm)
$886.00K
Revenue Growth
-61.96%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
30
Market Cap
1.59B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Guardian Pharmacy Services | 1.17B |
Evotec SE | 866.67M |
AtriCure | 447.57M |
BioCryst Pharmaceuticals | 412.58M |
Immunocore Holdings | 296.31M |
Arcus Biosciences | 263.00M |
Dynavax Technologies | 260.81M |
Travere Therapeutics | 203.45M |
SYRE News
- 2 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 3 days ago - Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire
- 4 days ago - Spyre Therapeutics Announces Grants of Inducement Awards - PRNewsWire
- 4 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Shareholders to Inquire about Securities Investigation - Accesswire
- 4 days ago - Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies - PRNewsWire
- 5 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Shareholders to Connect - Accesswire
- 7 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Stockholders to Inquire about Securities Investigation - Accesswire
- 8 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Investors to Learn More About the Investigation - Accesswire